Intellia pauses Phase 3 CRISPR trial as patient develops serious liver reaction to therapy called nex-z
Posted on: Oct 27, 2025 20:18 IST | Posted by: Livemint
Intellia Therapeutics has temporarily paused patient dosing and showing in its stage 3 MAGNITUDE and MAGNITUDE-2 trials for nex-z, a CRISPR-based therapy for transthyretin amyloidosis with myocardiopathy (ATTR-CM) and polyneuropathy (ATTR-PN). The reprieve follows a wicked safety event involving one participant.
According to the company, a patient in the MAGNITUDE trial who was dosed on September 30 developed Grade 4 liver transaminase elevations and increased total bilirubin, reported on October 24. The incident met the protocol’s criteria for pausing the study. The patient has been hospitalized and is receiving treatment while under close monitoring.
“In line with our commitment to patient safety, we have taken immediate action to temporarily pause enrollment in MAGNITUDE and MAGNITUDE-2 as we investigate this recent event,” CEO John Leonard, M.D., said in a statement. “As we focus on ensuring the health of this patient, we also are engaging with regulatory authorities and other stakeholders globally to develop a strategy to resume enrollment as soon as appropriate.”
Intellia is consulting experts and considering additional risk mitigation measures as it works through next steps.
Intellia Therapeutics providing an update said MAGNITUDE has enrolled more than 650 ATTR-CM patients to date, while 47 ATTR-PN patients have joined MAGNITUDE-2. The company estimates that over 450 patients have already been dosed with nex-z across both trials.
Nex-z uses CRISPR/Cas9 gene editing to permanently disable the TTR gene responsible for producing toxic transthyretin proteins. It is being developed as a potential one-time treatment for both ATTR-CM and ATTR-PN. Earlier clinical data showed deep and sustained TTR protein reductions after a single dose.
The therapy has received Orphan Drug and RMAT designation from the US Food and Drug Administration, along with Orphan Drug status in Europe. Intellia is leading development under a collaboration with Regeneron.
Intellia is among the first companies to take systemic CRISPR gene editing into late stage clinical trials. The company remains focused on developing therapies addressing unmet medical needs while expanding delivery and editing platforms for future programs.
Global News Perspectives
In today's interconnected world, staying informed about global events is more important than ever. ZisNews provides news coverage from multiple countries, allowing you to compare how different regions report on the same stories. This unique approach helps you gain a broader and more balanced understanding of international affairs. Whether it's politics, business, technology, or cultural trends, ZisNews ensures that you get a well-rounded perspective rather than a one-sided view. Expand your knowledge and see how global narratives unfold from different angles.
Customizable News Feed
At ZisNews, we understand that not every news story interests everyone. That's why we offer a customizable news feed, allowing you to control what you see. By adding keywords, you can filter out unwanted news, blocking articles that contain specific words in their titles or descriptions. This feature enables you to create a personalized experience where you only receive content that aligns with your interests. Register today to take full advantage of this functionality and enjoy a distraction-free news feed.
Like or Comment on News
Stay engaged with the news by interacting with stories that matter to you. Like or dislike articles based on your opinion, and share your thoughts in the comments section. Join discussions, see what others are saying, and be a part of an informed community that values meaningful conversations.
Download the Android App
For a seamless news experience, download the ZisNews Android app. Get instant notifications based on your selected categories and stay updated on breaking news. The app also allows you to block unwanted news, ensuring that you only receive content that aligns with your preferences. Stay connected anytime, anywhere.
Diverse News Categories
With ZisNews, you can explore a wide range of topics, ensuring that you never miss important developments. From Technology and Science to Sports, Politics, and Entertainment, we bring you the latest updates from the world's most trusted sources. Whether you are interested in groundbreaking scientific discoveries, tech innovations, or major sports events, our platform keeps you updated in real-time. Our carefully curated news selection helps you stay ahead, providing accurate and relevant stories tailored to diverse interests.
No comments yet.